-+ 0.00%
-+ 0.00%
-+ 0.00%

HC Wainwright & Co. Reiterates Neutral on Sage Therapeutics, Maintains $12 Price Target

Benzinga·06/17/2025 14:17:22
Listen to the news
HC Wainwright & Co. analyst Douglas Tsao reiterates Sage Therapeutics (NASDAQ:SAGE) with a Neutral and maintains $12 price target.